Wutah bathi EPS kuartalan vorbio.com (VOR)

The quarterly EPS growth rate is recorded at 98.40, highlighting the protection of Vor Biopharma Inc. (VOR) business by unique patents in gene synthesis. However, a narrow focus on leukemia therapy creates significant binary risks for investors. Nevertheless, Vor Biopharma Inc. (VOR) maintains its status as an authoritative player in oncohematology thanks to breakthrough bone marrow protection methods.

VOR: Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan Vor Biopharma 04.07.2022 - 14.11.2026

Vor Bio Inc. (VOR) - rincian metrik lan laporan keuangan

- nilai pasar lan prakiraan target analis:

Bagan rega Vor Biopharma|VOR - Rata-rata rega prakiraan

- rincian kapitalisasi pasar:

Kapitalisasi pasar Vor Bio|VOR - Nilai Bisnis

- indikator nilai aset resik miturut neraca:

Nilai Akuntansi saben Saham Vor Biopharma|VOR - Nilai Buku Perusahaan|Rasio Nilai Pasar marang Nilai Buku vorbio.com|VOR - Aset Perusahaan

- informasi babagan utang lan solvabilitas:

- informasi bathi lan kelipatan valuasi:

VOR - Penghasilan resik perusahaan|Bathi sing dikarepake Vor Biopharma Inc.|VOR - Kapitalisasi marang bathi resik|Pangali Forward P/E Vor Bio|VOR - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA Vor Bio|VOR - Bathi operasional EBITDA|Bathi saben saham sajrone rolas wulan pungkasan Vor Biopharma|VOR - Bathi saben saham sajroning taun lumaku|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan vorbio.com|VOR - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep Vor Biopharma Inc.

- informasi babagan volume dodolan lan pendapatan:

VOR - Pendapatan lan volume dodolan|Volume dodolan mangsa ngarep perusahaan Vor Biopharma|VOR - Rasio kapitalisasi pasar marang pendapatan|Multiplikator Forward P/S Vor Bio

Ringkesan analitik perusahaan:Vor Biopharma - VOR

Professional managers utilize fundamental filters to identify the intrinsic value of assets. This indicator measures the rate of change in earnings per share, reflecting the balance between market supply and demand. For Vor Biopharma Inc. (VOR), success depends on the commercialization of leukemia therapy and contracts with oncology centers. The dynamics of these processes determine the final change in quarterly earnings per share. Analyzing this chart helps identify the exhaustion of growth drivers in a timely manner.

Pesaing langsung